Compare Repligen Corporation Common Stock (RGEN) vs Viking Holdings Ltd Ordinary Shares (VIK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Viking Holdings Ltd Ordinary Shares — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Viking Holdings Ltd Ordinary Shares trades at $82.22 (market cap $36.70B). The key difference: Viking Holdings Ltd Ordinary Shares is far larger — about 3.3× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Viking Holdings Ltd Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Viking Holdings Ltd Ordinary Shares for 6 Days on average.
| RGEN | VIK | |
|---|---|---|
Market Cap | $11.14B | $36.70B |
Volume | 1,259,263 | 2,076,556 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $108.26 |
52-Week Low | $102.87 | $57.08 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $39.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Viking Holdings (VIK) trades at $82.16, up 1.72% on the day, with a bullish technical signal and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.31 exceeding expectations. Revenue for 2025 reached $6.50 billion, with a net income margin of 19.33%, while analyst consensus is strongly bullish with an 86.66% buy rating and a $107.92 price target. Recent news highlights fleet expansion, a $1 billion share repurchase program, and premium positioning in luxury travel.
VIK presents a compelling growth opportunity driven by strong bookings, expanding fleet, and premium valuations, though risks include execution on capital expenditure and sensitivity to travel disruptions. The stock's current price near key support at $81 suggests potential for upward movement toward resistance levels, supported by positive institutional sentiment and operational cash flow strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Viking Holdings Ltd Ordinary Shares
Viking operates river, ocean, and expedition cruises. Its itineraries focus on destination-based travel across Europe, the Americas, and other regions.
Read more on VIK →
